JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sgouros, G.
Right arrow Articles by Zelenetz, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sgouros, G.
Right arrow Articles by Zelenetz, A. D.
Journal of Nuclear Medicine Vol. 44 No. 2 260-268
© 2003 by Society of Nuclear Medicine


Basic Science Investigations

Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin’s Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of Tumor Dose-Response

George Sgouros, PhD, Shannon Squeri, BA, Åse M. Ballangrud, PhD, Katherine S. Kolbert, MS, Jerrold B. Teitcher, MD, Katherine S. Panageas, PhD, Ronald D. Finn, PhD, Chaitanya R. Divgi, MD, Steven M. Larson, MD and Andrew D. Zelenetz, MD, PhD

Memorial Sloan-Kettering Cancer Center, New York, New York

A comprehensive, SPECT-based, patient-specific 3-dimensional (3D) dosimetry analysis has been performed using 3D-ID, a previously developed software package. The role of the total-body tumor burden, individual lesion size, tumor absorbed dose, and the spatial distribution of the absorbed dose on response and on the time course of tumor shrinkage has been examined in patients with lymphoma treated by radioimmunotherapy. Methods: Data from 15 patients participating in a phase II study of 131I-labeled anti-B1 antibody (tositumomab) were used. Patients were administered a tracer dose of 131I for imaging and pharmacokinetics. Dose estimates from the tracer studies were used to prescribe the therapeutic administration such that the whole-body absorbed dose did not exceed 75 cGy. All patients received a fixed mass amount of antibody for both the tracer and the therapeutic administrations. SPECT and planar imaging were performed 3–4 d after the therapeutic administration. CT or MRI scans were available on all patients. Total tumor burden was assessed by drawing contours around all lymphoma lesions identified on whole-body CT or MRI. Mean absorbed doses were estimated for selected, index lesions by conventional dosimetry and also by 3D SPECT-based dosimetry. Using a patient-specific dosimetry package, 3D-ID, dose-volume histograms were also generated to assess the spatial distribution of absorbed dose. This approach made it possible to obtain estimates of the minimum and maximum absorbed doses for individual tumors in addition to the mean. Results: Mean absorbed dose estimates obtained by patient-specific SPECT-based dosimetry using 3D-ID were within 2%–5% of estimates obtained by conventional dosimetry. None of the absorbed dose parameters (mean, minimum, maximum, uniformity) were found to have a significant correlation with tumor response. The total-body tumor burden did not impact on overall response or toxicity. Conclusion: This analysis represents the first full reported implementation of a patient-specific 3D dosimetry package. The absence of a dose-response relationship for tumors is surprising and suggests that absorbed dose is not the sole determinant of tumor response in these patients. The absence of a correlation between the total-body tumor burden and overall response or toxicity suggests that tailoring the milligram amount of administered antibody to patient tumor burden is not likely to improve response or reduce toxicity.

Key Words: radioimmunotherapy • patient-specific dosimetry • 3D-ID software • tumor dose-response




This article has been cited by other articles:


Home page
JNMHome page
A. B. Delaloye, C. Antonescu, T. Louton, J. Kuhlmann, and A. Hagenbeek
Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial
J. Nucl. Med., November 1, 2009; 50(11): 1837 - 1843.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. R. Prideaux, H. Song, R. F. Hobbs, B. He, E. C. Frey, P. W. Ladenson, R. L. Wahl, and G. Sgouros
Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry
J. Nucl. Med., June 1, 2007; 48(6): 1008 - 1016.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. S. Kolbert, K. S. Pentlow, J. R. Pearson, A. Sheikh, R. D. Finn, J. L. Humm, and S. M. Larson
Prediction of Absorbed Dose to Normal Organs in Thyroid Cancer Patients Treated with 131I by Use of 124I PET and 3-Dimensional Internal Dosimetry Software
J. Nucl. Med., January 1, 2007; 48(1): 143 - 149.
[Abstract] [Full Text] [PDF]


Home page
J. Nucl. Med. Technol.Home page
H. K. Tan, R. W. Wassenaar, and W. Zeng
Collimator Selection, Acquisition Speed, and Visual Assessment of 131I-Tositumomab Biodistribution in a Phantom Model
J. Nucl. Med. Technol., December 1, 2006; 34(4): 224 - 227.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H. Song, B. He, A. Prideaux, Y. Du, E. Frey, W. Kasecamp, P. W. Ladenson, R. L. Wahl, and G. Sgouros
Lung Dosimetry for Radioiodine Treatment Planning in the Case of Diffuse Lung Metastases
J. Nucl. Med., December 1, 2006; 47(12): 1985 - 1994.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
Y. K. Dewaraja, S. J. Wilderman, M. Ljungberg, K. F. Koral, K. Zasadny, and M. S. Kaminiski
Accurate Dosimetry in 131I Radionuclide Therapy Using Patient-Specific, 3-Dimensional Methods for SPECT Reconstruction and Absorbed Dose Calculation
J. Nucl. Med., May 1, 2005; 46(5): 840 - 849.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. M. Goldenberg and R. M. Sharkey
Radioimmunotherapy of Non-Hodgkin's Lymphoma Revisited
J. Nucl. Med., February 1, 2005; 46(2): 383 - 384.
[Full Text] [PDF]


Home page
JNMHome page
G. Sgouros
Dosimetry of Internal Emitters
J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
R. M. Sharkey and D. M. Goldenberg
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
R. L. Wahl
Tositumomab and 131I Therapy in Non-Hodgkin's Lymphoma
J. Nucl. Med., January 1, 2005; 46(1_suppl): 128S - 140S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
E. J. Postema and K. E. Britton
Dosimetry and Radioimmunotherapy of Non-Hodgkin's Lymphoma
J. Nucl. Med., December 1, 2004; 45(12): 2126 - 2127.
[Full Text] [PDF]


Home page
JNMHome page
G. Sgouros, K. S. Kolbert, A. Sheikh, K. S. Pentlow, E. F. Mun, A. Barth, R. J. Robbins, and S. M. Larson
Patient-Specific Dosimetry for 131I Thyroid Cancer Therapy Using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) Software
J. Nucl. Med., August 1, 2004; 45(8): 1366 - 1372.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. A. Rizzieri, G. Akabani, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, E. Anderson, A. Lagoo, S. Clayton, et al.
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
Blood, August 1, 2004; 104(3): 642 - 648.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Du, J. Honeychurch, M. S. Cragg, M. Bayne, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
Blood, February 15, 2004; 103(4): 1485 - 1494.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder, A. Alavi, A. Matthies, D. E. Tsai, S. J. Schuster, E. A. Stadtmauer, et al.
Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response?
J. Nucl. Med., December 1, 2003; 44(12): 2000 - 2018.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. F. Koral, M. S. Kaminski, R. L. Wahl, G. Sgouros, S. Squeri, A. M. Ballanrud, K. Kolbert, J. B. Teitcher, K. S. Panageas, R. D. Finn, et al.
Correlation of Tumor Radiation-Absorbed Dose with Response Is Easier to Find in Previously Untreated Patients
J. Nucl. Med., September 1, 2003; 44(9): 1541 - 1543.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.